Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy

Abstract

ObjectiveTo evaluate the functional benefits (best corrected visual acuity (BCVA), central subfield thickness, injection loads, central venous pressure (CVP)) of a laser-induced chorioretinal anastomosis (L-CRA) in patients with central retinal vein occlusion (CRVO) treated with ranibizumab compared with ranibizumab monotherapy.Methods and AnalysisThis is a post-hoc analysis of the 2-year randomised ranibizumab plus L-CRA for CRVO trial. Twenty-four patients (82.5%) developed a functioning or successful L-CRA; outcome effects were monitored in the monthly as-needed ranibizumab phase from months 7 to 24 and compared with the ranibizumab monotherapy group (n=29).ResultsFrom months 7 to 24, the mean (95% CI) injection load for the functioning L-CRA group was 2.18 (1.57 to 2.78) compared with 7.07 (6.08 to 8.06) for the control group (p<0.0001). The mean BCVA was averaged across all timepoints between the control and functioning L-CRA groups (average difference=11.46 (3.16 to 19.75) letters, p=0.01). At 2 years, there was an 82.5% reduction in the odds of high CVP (greater or equal to central retinal artery diastolic pressure) for those with a successful L-CRA compared with controls (p<0.0001).ConclusionFor patients with CRVO, adding L-CRA as a causal-based treatment to conventional therapy reduced CVP and injection loads and offered improved BCVA.Trial registration number ACTRN12612000004864.

Influence of Retinal Venous Pressure on Visual and Structural Outcomes in Eyes with Central Retinal Vein Occlusion Undergoing Anti-VEGF Treatment

“……”

Influence of Retinal Venous Pressure on Visual and Structural Outcomes in Eyes with Central Retinal Vein Occlusion Undergoing Anti-VEGF Treatment

“……”

Chorioretinal venous anastomosis for non-ischemic retinal vein occlusion

“…It is reported in the literature that CRVA combined with intravitreal injection of anti-VEGF drugs can achieve a better therapeutic effect for treating RVO. In a two-year observation study ( 34 ), the results of the control group with an intravitreal injection of rezumab alone and the treatment group with an intravitreal injection of rezumab combined with L-CRVA in the PRN stage were compared. It was found that the average injection load of rezumab in the combined treatment group was 2.18 times (1.57 times to 2.78 times) in the first year.…”

Influence of Retinal Venous Pressure on Visual and Structural Outcomes in Eyes with Central Retinal Vein Occlusion Undergoing Anti-VEGF Treatment

“……”

Chorioretinal venous anastomosis for non-ischemic retinal vein occlusion

“…It is reported in the literature that CRVA combined with intravitreal injection of anti-VEGF drugs can achieve a better therapeutic effect for treating RVO. In a two-year observation study ( 34 ), the results of the control group with an intravitreal injection of rezumab alone and the treatment group with an intravitreal injection of rezumab combined with L-CRVA in the PRN stage were compared. It was found that the average injection load of rezumab in the combined treatment group was 2.18 times (1.57 times to 2.78 times) in the first year.…”

Influence of Retinal Venous Pressure on Visual and Structural Outcomes in Eyes with Central Retinal Vein Occlusion Undergoing Anti-VEGF Treatment

“……”

Chorioretinal venous anastomosis for non-ischemic retinal vein occlusion

“…It is reported in the literature that CRVA combined with intravitreal injection of anti-VEGF drugs can achieve a better therapeutic effect for treating RVO. In a two-year observation study ( 34 ), the results of the control group with an intravitreal injection of rezumab alone and the treatment group with an intravitreal injection of rezumab combined with L-CRVA in the PRN stage were compared. It was found that the average injection load of rezumab in the combined treatment group was 2.18 times (1.57 times to 2.78 times) in the first year.…”